Point72 Asset Management’s AnaptysBio ANAB Stock Holding History
Bought
Maintained
Sold
Other funds holding ANAB
EC
TCM
AAA
VCM
PAI
6CM
Point72 Asset Management's ANAB Position: Q1 2026 in Review
Point72 Asset Management reduced its AnaptysBio (ANAB) stake by 97% in Q1 2026, selling an estimated $101M and leaving 55,303 shares worth $3.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2029.
Point72 Asset Management first reported a position in ANAB in Q1 2019 and has held it in 21 quarters since. The position peaked at $93.7M in Q4 2025. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.
- Point72 Asset Management held 55,303 shares of AnaptysBio worth $3.07M as of Q1 2026.
- Point72 Asset Management sold 1,877,587 AnaptysBio shares in Q1 2026, an estimated $101M.
- AnaptysBio made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2029 holding.
- Point72 Asset Management first reported a position in AnaptysBio in Q1 2019 and has held it in 21 quarters since.
- Point72 Asset Management's AnaptysBio position peaked at $93.7M in Q4 2025.
- 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.